Needs special FDA pass for use in late-stage critical-ill patients to get some tractor. Looking from daily vol that many retail investors are in wait-see-mode on this stock?
Looks like someone is getting $$s from March stock price peak and at $4.99 it does not look like its over.
Company has in reality done nothing except recent patent app in PR area . . . and that's what will drive this early-stage biotech higher? No real support on charting and looking like going to $4-$.450 possibility. Just sit and wait if one believes in company and its tech.
Its already April . . . where is 2017 to be?
Why no USA Military backing on tech . . . Clock is ticking and China will . . . you know.
News 
Market Data 
Discover 
